Montelukast Sodium Tablet Recall Issued Due to Incorrect Drug In Bottles

Federal health officials have announced a recall for specific lots of sodium tablets, after finding that sealed bottles actually contained potassium tablets, posing an increased risk of blood pressure complications and renal dysfunction for individuals who take the wrong medication. 

The Montelukast Sodium Tablet recall was announced by the FDA on August 31, after it was discovered that Losartan Potassium Tablets may actually be inside of the sealed bottles.

The sodium tablets are designed to prevent wheezing, difficulty breathing, chest tightness and coughing caused by asthma, and are used to prevent breathing difficulties during exercise and seasonal allergies. It is part of a drug class called leukotriene receptor antagonists, which prohibit symptoms of asthma and allergies.

Did You Know?

Ticketmaster Data Breach Impacts Millions of Customers

A massive Ticketmaster data breach exposed the names, addresses, phone numbers, credit card numbers and other personal information of more than 560 million customers, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

According to the recall, the FDA has become aware that at least one lot of Montelukast Sodium Tablets were found to contain Losartan Potassium Tablets, which are used either alone or in combination with other medications to treat high blood pressure and to decrease the risk of stroke in patients with heart conditions.

The tablet mix-up poses an increased risk of renal dysfunction, elevated potassium levels, and low blood pressure. In severe cases, pregnant women accidently taking the blood pressure medication Losartan could put the fetus at serious risk of harm or death.

The recall includes bottles of 10 mg Montelukast Sodium Tablets containing 30 tablets with Lot number MON 17384, NDC number 31722-726-30 and have expiration date of December 31, 2019. The medications were manufactured by Camber Pharmaceuticals Inc., of Piscataway, New Jersey and were distributed to pharmacies and hospitals across the United States.

Patients with prescribed Montelukast Sodium Tablets should check the pills to ensure they are the correct prescription. Montelukast sodium tablets are beige, rounded square-shaped film coated tablets with “I” on one side and “114” on the other side. Losartan tablets are white and oval-shaped with the letter “I” printed on one side and the number “5” printed on the reverse.

Patients with the prescribed Montelukast medication should contact their healthcare provider or pharmacist to determine if their medicine is included in the recall. Those unsure of their prescription should check the drug name and company name of the label of the prescription bottle.

For further questions or concerns regarding the recall, patients are encouraged to contact the FDA at 888-INFO-FDA and to report any adverse health events to the FDA’s MedWatch Adverse Event Reporting program.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits
Ozempic MDL Court To Evaluate Need for Gastroparesis Diagnostic Testing in GLP-1 Lawsuits (Posted yesterday)

A federal judge has agreed to divide lawsuits over gastroparesis injuries linked to drugs like Ozempic and Mounjaro into multiple phases, examining how the condition is diagnosed and whether plaintiffs' claims are preempted by federal laws.

Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn
Adult Woman Files Similac Lawsuit Over NEC Injuries Experienced as a Newborn (Posted 2 days ago)

Lawsuit alleges that Abbott Laboratories failed to provide families and the medical community with adequate warnings about the risks associated with it’s cow’s milk-based Similac formula, which a now adult woman indicates has left her with life-long NEC injuries.

Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects
Amended Lawsuit Over BioZorb Implant Side Effects Outlines Problems Caused By Tissue Marker Design Defects (Posted 3 days ago)

Six breast cancer patients have asked a federal judge for permission to amend a complaint filed in March 2024, which describes problems linked to the device and painful side effects experienced when the tissue marker migrated out of position or shattered inside their bodies.